Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Follow-Up Questions
Passage Bio Inc (PASG)'in P/E oranı nedir?
Passage Bio Inc 'in P/E oranı N/A 'dir
Passage Bio Inc 'in CEO'su kimdir?
Mr. William Chou 2022 'den beri şirketle birlikte olan Passage Bio Inc 'in President 'ıdır.
PASG hissesinin fiyat performansı nasıl?
PASG 'in mevcut fiyatı 7.21 'dir, son işlem günde 4.4% decreased etti.
Passage Bio Inc için ana iş temaları veya sektörler nelerdir?
Passage Bio Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Passage Bio Inc 'in piyasa değerlemesi nedir?
Passage Bio Inc 'in mevcut piyasa değerlemesi $22.9 'dir
Passage Bio Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 6 analist Passage Bio Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 4 güçlü al, 6 al, 1 tut, 0 sat ve 4 güçlü sat içermektedir
